4/A: BioAge Labs COO's Spouse Receives Stock Option Award, Amending Previous Filing

Eric Morgen's spouse receives a stock option award from BioAge Labs, prompting an amendment to a previous SEC Form 4 filing.

Summary

• Eric Morgen, the Chief Operating Officer of BioAge Labs, filed an amended SEC Form 4 to report a stock option award granted to his spouse.
• The original filing on February 20, 2025, inadvertently omitted this transaction.
• The spouse received an option to buy 25,000 shares of common stock at an exercise price of $4.38.
• The option vests monthly over 48 months, starting February 1, 2025, subject to continued service.
• The option expires on February 17, 2035.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock options, indicating a neutral sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and insider transactions, common in publicly traded companies. It provides transparency into the equity-based compensation of key personnel and their families.

Related Party Transactions

• The stock option award to the spouse of Eric Morgen, the Chief Operating Officer, constitutes a related party transaction.

Stakeholder Impact

• The stock option award could potentially incentivize the COO and his spouse, aligning their interests with those of the shareholders.

Key Dates